Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Oncology·MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| hypercvad | AMGEN INC (AMGN) |
Phase 1(1)
| Drug | Company |
|---|---|
| blinatumomab | AMGEN INC (AMGN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia?
BioSniper tracks 2 drugs in development for Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia across 1 company.
How many clinical trials target Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia?
There are 1 clinical trial targeting Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia tracked by BioSniper.
Deep-dive into Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis